| Budget Amount *help |
¥5,330,000 (Direct Cost: ¥4,100,000、Indirect Cost: ¥1,230,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2013: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The aims of this study were to explore the expression profile of miRs and to evaluate the clinical significance of miRs expression in GBC. MiRs profile of surgically resected GBCs(n=26) and the GB with PBM(n=13) were assessed by microarray. Normal GBs(n=17) were also used as control. Up-regulated miR was subjected to quantitative reverse transcription polymerase chain reaction. The relationship between expression level of miR and clinicopathological features was analyzed. Microarray showed up-regulation of 25 miRs in GBCs. Among them, miR-155 was significantly overexpressed in GBCs than in GB with PBM(p=0.007) or normal GB(P=0.04). High expression level of miR-155 in GBCs was significantly associated with the presence of lymph node metastases(p=0.01) and poor prognosis (p=0.02). PBM did not affect regulation of miR-155. Thus, high miR-155 expression might correlate with aggressive behavior of GBCs and miR-155 would become a prognostic marker as well as a therapeutic target of GBCs.
|
